Journal of Public Health Policy

, Volume 34, Issue 1, pp 22–30 | Cite as

When falsified medicines enter the supply chain: Description of an incident in Kenya and lessons learned for rapid response

  • Jennifer Cohn
  • Tido von Schoen-Angerer
  • Elodie Jambert
  • Guido Arreghini
  • Michelle Childs
Original Article


Falsified and substandard medicines present serious concerns for public health. We describe an event that occurred in late 2011 involving falsified antiretroviral medicines found in the supplies of Médecins Sans Frontières (MSF) projects in Kenya. We discuss factors contributing to these falsified medicines entering the supply chain as well as the response by MSF and others. We make recommendations to help defend against future episodes of entry of falsified medicines into the supply chain as well as comments on appropriate responses in cases of falsified medicines.


falsified medicine antiretroviral therapy pharmacovigilance Kenya 


  1. World Health Organization. (2010) Medicines: spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines. Fact sheet N°275. (January) World Health Organization, Geneva,, accessed 23 March 2012.
  2. Caudron, J.M., Ford, N., Henkens, M., Mace, C., Kiddell-Monroe, R. and Pinel, J. (2008) Substandard medicines in resource-poor settings: A problem that can no longer be ignored. Tropical Medicine and International Health 13 (8): 1062–1072.CrossRefGoogle Scholar
  3. WHO. (2011) Report of the Working Group of Member States on Substandard/Spurious/Falsely-labeled/Falsified/Counterfeit Medical Products. 24 March,, accessed 30 July 2012.
  4. Time to focus on quality. (February 2011) MSF Briefing Note ahead of the February 2011 meeting of the Working Group of WHO Member States on Substandard/spurious/falsely-labelled/falsified/counterfeit medical products. Médecins Sans Frontières,, accessed 24 September 2012.
  5. Park, C.S. (2009) Legal Aspects of Defining ‘Counterfeit Medicines’: A Discussion Paper. New Delhi: World Health Organization, Regional Office for South East Asia.Google Scholar
  6. WHO. (2012) Prequalification of Medicines by the WHO. Factsheet,, accessed 30 July 2012.
  7. Prequalification of Medicines Programme. (2011) Additional information regarding falsified lamivudine, zidovudine and nevirapine tablets (Zidolam-N) in Kenya (6 October 2011) WHO Prequalification of Medicines Programme,, accessed 23 March 2012.
  8. MSF Access Campaign. (2011) Falsified lamivudine, zidovudine and nevirapine tablets(Zidolam-N) in Kenya (23 September 2011),, accessed 23 March 2012.
  9. Falsified Medicines Enter Supply Chain in Kenya. (30 September 2011) Médecins Sans Frontières Press Release,, accessed 23 March 2012.
  10. Kenya National Council for Law Reporting. (2010) The Industrial Property Act,, accessed 30 July 2012.
  11. WHO. (1999) Guidelines for the development of measures to combat counterfeit drugs. January,, accessed 30 July 2012.
  12. Republic of Kenya High Court. (2009) Republic of Kenya in the High Court of Kenya at Nairobi Petition No. 409 of 2009,, accessed 30 July 2012.
  13. Musungu, S. (2010) The Potential Impact of the Proposed East African Community (EAC) Anti-Counterfeiting Policy and Bill on Access to Essential Medicines. UNDP Commissioned Discussion Paper.Google Scholar

Copyright information

© Palgrave Macmillan, a division of Macmillan Publishers Ltd 2012

Authors and Affiliations

  • Jennifer Cohn
    • 1
  • Tido von Schoen-Angerer
    • 2
  • Elodie Jambert
    • 2
  • Guido Arreghini
    • 3
  • Michelle Childs
    • 2
  1. 1.University School of Medicine, University of PennsylvaniaPhiladelphiaUSA
  2. 2.Médecins Sans FrontièresGeneva,Switzerland
  3. 3.Médecins Sans FrontièresNairobiKenya

Personalised recommendations